Valeo Financial Advisors
ITCI icon

Valeo Financial Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Valeo Financial Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-559
Closed -$7K – 1698
2019
Q2 		$7K Buy
+559
New +$7.17K ﹤0.01% 1133

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Samlyn Capital
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Valeo Financial Advisors's ITCI Position: Q3 2019 in Review

Valeo Financial Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2019, closing a stake of 559 shares — an estimated $7K sold.

Valeo Financial Advisors first reported a position in ITCI in Q2 2019 and held it in 1 quarter. The position peaked at $7K in Q2 2019. 126 funds tracked by Wall St. Rank hold ITCI as of Q3 2019.

  • Valeo Financial Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 559 Intra-Cellular Therapies Inc. shares in Q3 2019, an estimated $7K.
  • Valeo Financial Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and held it in 1 quarter.
  • Valeo Financial Advisors's Intra-Cellular Therapies Inc. position peaked at $7K in Q2 2019.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2019.

Based on Valeo Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.